FCY2 Antibody

What is FCY2 and what are its primary functions in different organisms?

FCY2 refers to a gene that encodes purine-cytosine permease (PCP) in fungal species such as Candida lusitaniae. This permease is responsible for the active transport of molecules like flucytosine (5FC) into fungal cells. The protein plays a critical role in the uptake and metabolism of antifungal agents .

In research contexts, it's important to distinguish between the fungal FCY2 gene/protein and the human FCRL2 (Fc receptor-like 2, also known as FcRH2) protein. Though similar in abbreviation, these are distinct molecules with different functions - FCRL2 is a human protein belonging to the family of glycoprotein homologs of classical immunoglobulin Fc receptors, expressed primarily in B cells .

How is FCY2 expression typically analyzed in research settings?

For fungal FCY2 expression analysis, researchers typically employ:

• Transcriptional analysis: RT-PCR or qPCR to quantify FCY2 mRNA levels, as demonstrated in studies of clinical isolates where "levels of transcription of the FCY2 gene encoding purine-cytosine permease (PCP) in the isolates were similar to that in the wild-type strain" .

• Functional assays: Measuring the uptake of substrates such as 5FC to evaluate permease activity indirectly.

For human FCRL2/FcRH2 detection, flow cytometry is commonly used, as described in protocols where "Human whole blood CD19+ B cells were stained with Goat Anti-Human FCRL2/FcRH2 Antigen Affinity-purified Polyclonal Antibody followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody" .

What experimental systems are most appropriate for studying FCY2-related mechanisms?

For fungal FCY2 studies, the haploid yeast Candida lusitaniae has emerged as an excellent model organism. As noted in the literature, "Candida lusitaniae (teleomorph, Clavispora lusitaniae) is a good model for studying antifungal resistance" . This organism is particularly valuable because it readily develops resistance to antifungal agents during treatment.

For human FCRL2/FcRH2 studies, research typically employs:

• Isolated human B cells (especially CD19+ B cells from peripheral blood)

• B cell lines expressing FCRL2

• Tissue samples from lymphoid organs such as spleen, lymph nodes, and tonsils

What are the known mutations in FCY2 and how do they affect protein function?

Several key mutations in the FCY2 gene have been identified that impact protein function:

• C505T nonsense mutation: A cytosine-to-thymine substitution at nucleotide 505 results in a truncated, non-functional PCP protein of only 168 amino acids. This mutation has been documented in seven clinical isolates and correlates with both 5FC resistance and 5FC/FLC cross-resistance .

• The study states that "we demonstrated that only two genetic events occurred in 11 unrelated clinical isolates of C. lusitaniae to support 5FC and 5FC/FLC resistance: either the nonsense mutation C505T in the fcy2 gene or the missense mutation T26C in the fcy1 gene" .

How do mutations in FCY2 contribute to antifungal resistance mechanisms?

The FCY2-encoded purine-cytosine permease is essential for transporting 5FC into fungal cells. When mutations occur in this gene (such as the C505T nonsense mutation), the resulting truncated protein is incapable of facilitating 5FC uptake, rendering the antifungal ineffective .

Moreover, research has revealed an unexpected cross-resistance phenomenon: "In addition, these strains were specifically cross-resistant to fluconazole (FLC) when both antifungals, 5FC and FLC, were used in combination. It was then hypothesized that extracellular 5FC would behave as a competitive inhibitor of FLC uptake" . This suggests a complex interaction between drug transport systems that extends beyond the direct function of the permease.

This cross-resistance pattern is particularly significant for clinical treatment strategies, as shown in the following resistance profiles from clinical isolates:

What are the technical challenges in differentiating between FCY2 and other related genes or proteins?

Researchers face several challenges when studying FCY2 and related systems:

• Sequence homology confusion: The FCY gene family in fungi includes several related genes (FCY1, FCY2, etc.) with similar functions but distinct roles in antifungal metabolism. Careful primer design and sequence analysis are required to specifically target FCY2.

• Cross-reactivity in antibody-based detection: For human FCRL2/FcRH2 studies, the protein belongs to "the family of glycoprotein homologs of classical immunoglobulin (Ig) Fc receptors" which "contains from three to nine immunoglobulin-like domains" . This homology can lead to cross-reactivity in immunological detection methods.

• Differential expression patterns: Expression of FCRL2 varies among B cell populations, being "preferentially expressed on naïve and CD27+ memory B cells within the spleen, lymph nodes, tonsils, and peripheral blood" . This requires careful sample selection and population identification.

How can genetic manipulation approaches be optimized for studying FCY2 function?

Research has demonstrated several effective genetic manipulation strategies:

• Gene replacement: The definitive approach to confirming the functional impact of FCY2 mutations involves replacing the mutated gene with a wild-type copy. As described in the literature, "Reintroducing a FCY2 wild-type allele at the fcy2 locus of a ura3 auxotrophic strain derived from the clinical isolate CL38 fcy2(C505T) restored levels of susceptibility to antifungals comparable to those of the wild-type strains" .

• Transformation protocol optimization: For C. lusitaniae, researchers found that linearizing plasmids "within FCY2 (BamHI restriction site), FCY21 (BamHI restriction site), or URA3 (PstI restriction site), respectively, in order to obtain a greater efficiency of plasmid integration at the relevant homologous locus" .

• Selective markers: Using the URA3 gene as a selectable marker has proven effective, with "Ura+ transformants... selected on YNB medium supplemented with 1 M sorbitol after 3 to 4 days of incubation at 35°C" .

What are the emerging roles of FCY2/FCRL2 in disease pathogenesis and potential therapeutic interventions?

For fungal FCY2:

• Mutations in this gene represent a critical mechanism of antifungal resistance, particularly in C. lusitaniae, which has "a propensity to develop resistance to antifungal agents during treatment, mainly to amphotericin B, but also to azole drugs and to flucytosine (5FC)" .

• Understanding FCY2 mutations provides a molecular basis for adjusting therapeutic strategies when treating resistant fungal infections.

For human FCRL2/FcRH2:

• Research indicates potential roles in B cell malignancies, as "the gene for FcRH2 maps to the human Iq21-23 locus which is a hotspot for chromosomal translocation events associated with B cell malignancies" .

• FCRL2 expression serves as a potential biomarker in certain leukemias, being "expressed on most B cells in B cell chronic lymphocytic leukemia (B‐CLL) patients" and "FCRL2 up‐regulation is associated with mutation of the immunoglobulin heavy chain variable (IGHV) and less aggressive forms of B-CLL" .

What are the optimal protocols for antibody-based detection of FCRL2/FcRH2?

For flow cytometry detection of human FCRL2/FcRH2, the following protocol has proven effective:

• Sample preparation: Isolate CD19+ B cells from human whole blood.

• Primary antibody staining: Apply Goat Anti-Human FCRL2/FcRH2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2048).

• Secondary detection: Use Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108).

• Co-staining: Include Human CD19 Phycoerythrin-conjugated Monoclonal Antibody (Catalog # FAB4867P) for B cell identification.

• Controls: Set quadrant markers based on control antibody staining (Catalog # AB-108-C) .

Storage recommendations for optimal antibody performance include:

• 12 months from date of receipt at -20 to -70 °C as supplied

• 1 month at 2 to 8 °C under sterile conditions after reconstitution

• 6 months at -20 to -70 °C under sterile conditions after reconstitution

How can researchers effectively design experiments to study FCY2 mutations and their functional impacts?

Based on successful research approaches, an effective experimental design would include:

• Initial characterization:

  • Sequence analysis of FCY2 genes from clinical or laboratory isolates

  • Transcriptional analysis to verify expression levels

  • Phenotypic assessment of antifungal susceptibility

• Functional validation:

  • Create genetically modified strains with specific FCY2 mutations

  • Complementation studies reintroducing wild-type FCY2 into mutant strains

  • Comparative growth assays in the presence of antifungals

• Mechanistic investigation:

  • Direct measurement of drug uptake in wild-type versus mutant strains

  • Structural modeling of PCP to understand how mutations affect function

  • Epistasis analysis with other genes in the antifungal resistance pathway

As demonstrated in published research, "On the basis of gene replacement experiments, we first demonstrated that in seven clinical isolates, 5FC resistance and 5FC/FLC cross-resistance were correlated with a single cytosine-to-thymine substitution at nucleotide 505 in the fcy2 gene" .

What controls and validation steps are critical when investigating FCY2/FCRL2 expression and function?

Essential controls and validation steps include:

For fungal FCY2 studies:

• Include wild-type reference strains alongside mutants (e.g., the reference strain 6936)

• Verify gene replacement by sequence analysis

• Include complementation controls showing restored phenotype with wild-type gene introduction

• Test multiple independent transformants to rule out position effects

For human FCRL2/FcRH2 studies:

• Include appropriate isotype control antibodies

• Validate antibody specificity using FCRL2-negative and FCRL2-positive cell populations

• Perform cross-adsorption studies if other FCRL family members are present

• Include multiple B cell populations to account for differential expression patterns

How can contradictory data regarding FCY2 function be reconciled in research contexts?

When facing contradictory results in FCY2 research, consider these approaches:

• Genetic background effects: Different strain backgrounds may contain modifiers that affect FCY2 function. For instance, research has shown strain-specific differences in clinical isolates of C. lusitaniae .

• Technical variables: Discrepancies may arise from differences in:

  • Growth conditions (medium, temperature, pH)

  • Drug concentration ranges tested

  • Measurement methods (e.g., growth inhibition versus direct uptake assays)

• Multiple resistance mechanisms: As demonstrated in the literature, "the molecular events supporting resistance could be correlated with a single thymine-to-cytosine substitution at nucleotide 26 in the fcy1 gene, resulting in the amino acid substitution M9T at the protein level" , showing that phenotypically similar resistance can arise from distinct genetic causes.

• Expression-level differences: While gross gene deletions clearly affect function, more subtle expression differences might produce contradictory results. The research noted that "the levels of transcription of the FCY2 gene encoding purine-cytosine permease (PCP) in the isolates were similar to that in the wild-type strain" , highlighting the importance of measuring both expression and sequence.

What are the emerging technologies enabling more precise analysis of FCY2/FCRL2 biology?

Recent technological advances driving FCY2/FCRL2 research include:

• CRISPR-Cas9 gene editing: Allowing precise introduction of specific mutations to study their functional consequences in both fungal and human cell models.

• Single-cell analysis techniques: Enabling detailed characterization of FCRL2 expression across B cell populations at different developmental stages and in disease contexts.

• Structural biology approaches: Providing insights into the three-dimensional structure of transporters like PCP, facilitating understanding of how mutations affect function.

• High-throughput screening: Permitting rapid assessment of compound libraries for molecules that might overcome resistance conferred by FCY2 mutations.

How do species differences in FCY2 structure and function impact research translation?

Important species considerations in FCY2 research include:

• Absence of direct orthologs: Research indicates that "Although there are several Fc receptor‐like genes in the mouse, none of these is a clear ortholog to human FCRL2" , complicating the use of mouse models for studying human FCRL2 biology.

• Fungal species differences: While C. lusitaniae serves as a model organism, other pathogenic fungi like Cryptococcus neoformans also show FCY2-related resistance mechanisms, but with potential differences in gene regulation and protein structure .

• Translation challenges: When developing interventions targeting FCY2-dependent mechanisms, species-specific differences must be considered to ensure effective translation to clinical applications.

These species differences emphasize the importance of selecting appropriate model systems and being cautious when extrapolating findings across species boundaries.

What are the key unresolved questions in FCY2/FCRL2 research?

Despite significant advances, several important questions remain:

• For fungal FCY2:

  • How do transport proteins like PCP interact with other drug efflux systems?

  • What structural features of the permease determine substrate specificity?

  • How widespread are the identified resistance mutations across clinical isolates from different geographical regions?

• For human FCRL2/FcRH2:

  • What are the precise signaling pathways downstream of FCRL2 activation?

  • How does FCRL2 expression modulate B cell function in health and disease?

  • Can FCRL2 serve as a therapeutic target for B cell malignancies?